Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of
phosphatidylcholine and cholesterol. Liposomal doxorubicin can extravasate into tumors with
abnormal vascular endothelium but may not penetrate normal tissues lowering its toxicity and
increasing its efficiency. Combining Liposomal doxorubicin with cisplatin could be an
effective new chemotherapy treatment for malignant pleural mesothelioma .
Hypothesis:
Liposomal doxorubicin combined with cisplatin could increase response rates to chemotherapy,
progression free survival and overall survival in patients with malignant pleural
mesothelioma.